trial

Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.

NCTId NCT07547384
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Not Yet Recruiting
Enrollment 116 (estimated)
Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Primary completion 2027-09-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Not Yet Recruiting
Enrollment
116 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2026-04-05
Primary completion
2027-09-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Lead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
116
Phase
NA
Primary Completion Date
2027-09-05
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication